Bellevue Group Ag Incyte Corp Transaction History

Bellevue Group Ag

$5.93 Billion
Q3 2024

A detailed history of Bellevue Group Ag transactions in Incyte Corp stock. As of the latest transaction made, Bellevue Group Ag holds 2,150,551 shares of INCY stock, worth $148 Million. This represents 2.4% of its overall portfolio holdings.

Number of Shares

2,150,551

Previous 2,153,504 0.14%

Holding current value

$148 Million

Previous $131 Million 8.89%

% of portfolio

2.4%

Previous 2.18%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$57.33 - $68.61 $169,295 - $202,605	-2,953 Reduced 0.14%	2,150,551 $142 Million
Q2 2024 Aug 14, 2024	BUY	$51.18 - $63.75 $5,936 - $7,395	116 Added 0.01%	2,153,504 $131 Million
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $188,368 - $221,811	-3,331 Reduced 0.15%	2,153,388 $123 Million
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $17.5 Million - $21.5 Million	-334,731 Reduced 13.44%	2,156,719 $135 Million
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $8.63 Million - $9.84 Million	-149,315 Reduced 5.65%	2,491,450 $144 Million
Q2 2023 Aug 14, 2023	SELL	$60.95 - $75.51 $12.2 Million - $15.1 Million	-199,735 Reduced 7.03%	2,640,765 $164 Million
Q1 2023 May 15, 2023	SELL	$70.23 - $86.01 $8.18 Million - $10 Million	-116,477 Reduced 3.94%	2,840,500 $205 Million
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $14.3 Million - $17.9 Million	212,700 Added 7.75%	2,956,977 $238 Million
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $1.93 Million - $2.41 Million	-29,100 Reduced 1.05%	2,744,277 $183 Million
Q2 2022 Aug 11, 2022	SELL	$66.18 - $83.18 $4.9 Million - $6.16 Million	-74,023 Reduced 2.6%	2,773,377 $211 Million
Q1 2022 May 13, 2022	SELL	$66.02 - $79.71 $7.24 Million - $8.74 Million	-109,600 Reduced 3.71%	2,847,400 $226 Million
Q3 2021 Nov 12, 2021	SELL	$68.67 - $84.02 $988,848 - $1.21 Million	-14,400 Reduced 0.48%	2,957,000 $203 Million
Q2 2021 Aug 12, 2021	SELL	$79.87 - $87.53 $2.74 Million - $3 Million	-34,300 Reduced 1.14%	2,971,400 $250 Million
Q1 2021 May 12, 2021	SELL	$76.02 - $100.5 $228,060 - $301,500	-3,000 Reduced 0.1%	3,005,700 $244 Million
Q4 2020 Feb 16, 2021	SELL	$80.74 - $97.7 $21.9 Million - $26.5 Million	-270,750 Reduced 8.26%	3,008,700 $262 Million
Q3 2020 Nov 16, 2020	SELL	$85.07 - $109.69 $1.12 Million - $1.44 Million	-13,150 Reduced 0.4%	3,279,450 $294 Million
Q2 2020 Aug 13, 2020	SELL	$74.18 - $108.93 $2.33 Million - $3.42 Million	-31,400 Reduced 0.94%	3,292,600 $342 Million
Q1 2020 May 14, 2020	SELL	$63.18 - $85.97 $12.2 Million - $16.6 Million	-193,000 Reduced 5.49%	3,324,000 $243 Million
Q4 2019 Feb 14, 2020	SELL	$73.04 - $95.72 $13.1 Million - $17.2 Million	-179,200 Reduced 4.85%	3,517,000 $307 Million
Q3 2019 Nov 14, 2019	SELL	$72.82 - $86.52 $105,588 - $125,454	-1,450 Reduced 0.04%	3,696,200 $274 Million
Q2 2019 Aug 14, 2019	BUY	$73.52 - $88.7 $268 Million - $324 Million	3,649,150 Added 7524.02%	3,697,650 $314 Million
Q1 2019 May 15, 2019	SELL	$63.56 - $88.17 $645,134 - $894,925	-10,150 Reduced 17.31%	48,500 $4.17 Million
Q4 2018 Feb 12, 2019	BUY	$58.5 - $69.94 $368,550 - $440,622	6,300 Added 12.03%	58,650 $3.73 Million
Q3 2018 Nov 13, 2018	SELL	$61.75 - $74.23 $154,375 - $185,575	-2,500 Reduced 4.56%	52,350 $3.62 Million
Q2 2018 Aug 07, 2018	SELL	$60.85 - $83.98 $10.7 Million - $14.8 Million	-175,776 Reduced 76.22%	54,850 $3.68 Million
Q1 2018 May 09, 2018	SELL	$83.06 - $100.98 $78,907 - $95,931	-950 Reduced 0.41%	230,626 $19.2 Million
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $7.97 Million - $9.94 Million	85,210 Added 58.22%	231,576 $21.9 Million
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $2.51 Million - $3.17 Million	22,954 Added 18.6%	146,366 $17.1 Million
Q2 2017 Aug 14, 2017	BUY	N/A	123,412	123,412 $15.5 Million

Others Institutions Holding INCY

# of Institutions

643

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Incyte Corp Transaction History